References
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2017.
- Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96(12):3948–3952.
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
- Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014;99(3):458–464.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
- McCoach CE, Blumenthal GM, Zhang L, et al. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017;28:2707–2714.
- Camidge D, Tiseo M, Anh M, et al. Depth of target lesion response to brigatinib and its association with outcomes in patients with ALK+ NSCLC in the ALTA trial. Paper presented at: IASLC World Conference on Lung Cancer; 2017; Yokohama, Japan.
- Morgensztern D, O”Brien M, Ong T, et al. Impact of depth of response on survival in patients with advanced NSCLC treated with first-line chemotherapy. J Thorac Oncol. 2017;12(1):S387–S388.
- Wu T, Hsiue E, Lee J, et al. Depth of response to first-line EGFR TKI does not predict survival in EGFR- mutated NSCLC patients. J Thorac Oncol. 2017;12(1):S386–S387.
- Rosell R, Karachaliou N. Trends in immunotherapy for brain metastases. Lancet Oncol. 2016;17(7):859–860.
- Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417.
- Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663–671.
- Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31(30):3764–3775.
- Mansmann U, Sartorius U, Laubencer R, et al. Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J Clin Oncol. 2013;31(4_suppl (February 1 Supplement)): 427. (2013 Gastrointestinal Cancers Symposium (January 24–26, 2013)).
- Tsuji A, Sunakawa Y, Ichikawa W, et al. Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05). Target Oncol. 2016;11(6):799–806.
- Cremolini C, Loupakis F, Antoniotti C, et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015;26(6):1188–1194.
- Lee CK, Kim SS, Park S, et al. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget. 2017;8(19):31169–31179.